H.R. 1227: Alternatives to PAIN Act

H.R. 1227, the Alternatives to PAIN Act, changes how Medicare Part D treats certain non-opioid pain drugs. Starting with 2026 plan years, a qualifying drug would skip the Part D deductible entirely and sit on the plan's lowest cost-sharing tier — the cheapest copay rung instead of the specialty tier where new brand drugs often land.

It also strips out two common insurance gatekeepers. Plans could not require prior authorization for a qualifying drug, and they could not run step therapy that forces a patient to use an opioid before the non-opioid drug is covered. The same deductible and low-tier protections extend to people on Medicare's low-income subsidy.

The catch is the definition. A drug only qualifies if the FDA has approved it for postoperative or other acute pain, it does not act on the body's opioid receptors, no therapeutically equivalent product is already sold in the U.S., and a month's supply stays under Medicare's specialty-tier price ceiling. Together those tests point at a small set of newer brand-name drugs — the FDA approved the first non-opioid in this acute-pain class, suzetrigine (Journavx), in January 2025 — not the broad world of non-opioid pain care like generic ibuprofen.

Sponsors frame the bill as addiction prevention: if insurance rules make opioids the path of least resistance, patients may end up on them even when a non-opioid would do. The harder question for committees is cost — lowering cost-sharing and removing plan management tools for a class of higher-priced brand drugs could raise Medicare spending, and the bill carries no estimate.